Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition [0.03%]
靶向表观基因和免疫逃逸：蛋白精氨酸甲基转移酶5抑制的新篇章
P A Shah,J Rodon
P A Shah
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma [0.03%]
新辅助免疫治疗后，临床可见III期黑色素瘤的病灶评估在减少肿瘤病灶检查的情况下仍然准确计算病理反应
R V Rawson,N G Maher,A M Menzies et al.
R V Rawson et al.
Background: Neoadjuvant immunotherapy produces event-free survival advantage over adjuvant therapy for patients with surgically resectable macroscopic stage IIIB/C/D melanoma. Pathologic response, determined as % residual...
Nivolumab and Cabozantinib Combination Therapy Demonstrates Sustained Efficacy in Metastatic Renal Cell Carcinoma [0.03%]
尼伏单抗和卡博替尼联合治疗转移性肾细胞癌显示出持续疗效
Z A Yochum,D A Braun
Z A Yochum
Rethinking Survival Metrics in EGFR-Mutated NSCLC: Insights from RMST Analysis of FLAURA2 and MARIPOSA [0.03%]
重新思考EGFR突变型NSCLC中的生存指标：FLAURA2和MARIPOSA试验限制平均寿命分析的见解
F Acker,M Rost,M Sebastian et al.
F Acker et al.
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer [0.03%]
前列腺癌雄激素受体基因座改变的谱系及临床分级
T Virtanen,E M Kwan,K Parekh et al.
T Virtanen et al.
Background: Somatic alterations to the androgen receptor (AR) gene are pivotal drivers of treatment resistance in metastatic castration-resistant prostate cancer (mCRPC), but their prevalence, clinical impact, and etiolog...
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial [0.03%]
新辅助德鲁替康或联合白蛋白结合型紫杉醇、曲妥珠单抗和帕妥珠单抗治疗高危HER2阳性早期乳腺癌（DESTINY-Breast11）：一项随机、开放标签、多中心的Ⅲ期试验
Nadia Harbeck,Shanu Modi,Lajos Pusztai et al.
Nadia Harbeck et al.
Background: Neoadjuvant standard-of-care for HER2-positive early-stage breast cancer is trastuzumab+pertuzumab with polychemotherapy; however, existing regimens have high toxicity burdens and suboptimal outcomes. DESTINY-...
Response to 'A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer' [0.03%]
对“提出的一种用于转移性结直肠癌的风险调整监测算法存在的一个时间悖论”的回应
M M Germani,D P Modest
M M Germani
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy [0.03%]
SERENA-6试验：Camizestrant联合CDK4/6抑制剂治疗一线内分泌治疗中出现新兴ESR1突变的晚期乳腺癌患者的患者报告结局
E L Mayer,F-C Bidard,Y H Park et al.
E L Mayer et al.
Background: In SERENA-6, switching from aromatase inhibitor (AI) to camizestrant with continuation of CDK4/6 inhibitor (CDK4/6i) guided by emergence of ESR1m during first-line AI-CDK4/6i in patients with HR+ advanced brea...
Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC [0.03%]
生存改善和发病率上升：来自NSCLC患者脑膜转移最大规模回顾性研究的见解
J W J Huijs,E Le Rhun,L E L Hendriks
J W J Huijs
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study [0.03%]
来自NSCLC的脑膜转移的演变：一项国际性、多中心队列研究
M M Zheng,Y Xia,K Pan et al.
M M Zheng et al.
Background: Leptomeningeal metastatic disease (LMD) represents a devastating complication of non-small-cell lung cancer (NSCLC) with a poor prognosis. Our understanding of LMD is limited in the era of molecular testing an...